Evaluation of antitumor activity of survivin short interfering RNA delivered by lipid nanoparticles in colon cancer in vitro and in vivo

Wang,Tianyou; Liu,Ziqin; Zhang,Zhaoxia; Tang,Suoqin; Yue,Mei; Feng,Shunqiao; Hu,Mengze; Xuan,Litian; Chen,Yanfei

doi:10.3892/ol.2017.6404

Evaluation of antitumor activity of survivin short interfering RNA delivered by lipid nanoparticles in colon cancer in vitro and in vivo

Authors:
- Tianyou Wang
- Ziqin Liu
- Zhaoxia Zhang
- Suoqin Tang
- Mei Yue
- Shunqiao Feng
- Mengze Hu
- Litian Xuan
- Yanfei Chen
View Affiliations

Affiliations: Department of Hematology and Oncology, Beijing Children's Hospital, Capital Medicine University, Beijing 100045, P.R. China, Department of Pediatrics, Capital Institute of Pediatrics, Beijing 100020, P.R. China, Department of Hematology and Oncology, Capital Institute of Pediatrics, Beijing 100020, P.R. China, Department of Pediatrics, Chinese People's Liberation Army General Hospital, Beijing 100853, P.R. China
Published online on: June 16, 2017 https://doi.org/10.3892/ol.2017.6404
Pages: 2001-2008
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Survivin has been overexpressed in numerous types of cancer and is associated with a poor clinical outcome. A number of various approaches have been used to counteract survivin in order to inhibit tumor growth or promote cell apoptosis. The present study aimed to evaluate the efficiency and antitumor effect of a survivin‑targeted short interfering RNA (siRNA) delivery system using lipid nanoparticles for the treatment of colon cancer. Survivin siRNA (si‑survivin) nanoliposomes were prepared and transfected into LoVo cells. The mRNA expression level of survivin was determined by reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) and western blot analysis. Cell viability was evaluated by MTT assay. LoVo‑bearing nude mice were treated with si‑survivin intratumorally or intravenously. Tumor growth in LoVo‑bearing mice was monitored and recorded, and tumor samples were obtained for evaluation of survivin expression levels using RT‑qPCR, western blotting and immunohischemical staining. The expression level of survivin was significantly reduced by nanoliposomal si‑survivin along with cell proliferation inhibition in vitro. Intravenous administration of si‑survivin nanoliposomes may significantly inhibit tumor growth with less toxicity compared with doxorubicin hydrochloride treatment in LoVo‑bearing mice. Nanoliposomal si‑survivin may significantly reduce the expression level of survivin and inhibit cell proliferation of colon cancer cells in vitro and in vivo. si‑survivin delivered by lipid nanoparticles may be a potential treatment approach for colon cancer.

View Figures

View References

1	Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
2	Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC and Altieri DC: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 396:580–584. 1998. View Article : Google Scholar : PubMed/NCBI
3	Sah NK, Khan Z, Khan GJ and Bisen PS: Structural, functional and therapeutic biology of survivin. Cancer Lett. 244:164–171. 2006. View Article : Google Scholar : PubMed/NCBI
4	Zaffaroni N and Daidone MG: Survivin expression and resistance to anticancer treatments: Perspectives for new therapeutic interventions. Drug Resist Updat. 5:65–72. 2002. View Article : Google Scholar : PubMed/NCBI
5	Moriai R, Asanuma K, Kobayashi D, Yajima T, Yagihashi A, Yamada M and Watanabe N: Quantitative analysis of the anti-apoptotic gene survivin expression in malignant haematopoietic cells. Anticancer Res. 21:595–600. 2001.PubMed/NCBI
6	Notarbartolo M, Cervello M, Dusonchet L, Cusimano A and D'Alessandro N: Resistance to diverse apoptotic triggers in multidrug resistant HL60 cells and its possible relationship to the expression of P-glycoprotein, Fas and of the novel anti-apoptosis factors IAP (inhibitory of apoptosis proteins). Cancer Lett. 180:91–101. 2002. View Article : Google Scholar : PubMed/NCBI
7	Troeger A, Siepermann M, Escherich G, Meisel R, Willers R, Gudowius S, Moritz T, Laws HJ, Hanenberg H, Goebel U, et al: Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia. Haematologica. 92:1043–1050. 2007. View Article : Google Scholar : PubMed/NCBI
8	Moriyama M, Kano R, Maruyama H, Hasegawa A and Kamata H: Small interfering RNA (siRNA) against the survivin gene increases apoptosis in a canine melanoma cell line. J Vet Med Sci. 72:1643–1646. 2010. View Article : Google Scholar : PubMed/NCBI
9	Cai M, Wang G, Tao K and Cai C: Induction of apoptosis of human colon cancer cells by siRNA recombinant expression vector targeting survivin gene. J Huazhong Univ Sci Technolog Med Sci. 29:45–49. 2009. View Article : Google Scholar : PubMed/NCBI
10	Li J, Yue M, Shi X, Feng S, Tang R, Zhang X, Liu R, Liu Z and Wang T: Evaluation of anti-cancer activity of survivin siRNA delivered by folate receptor-targeted polyethylene-glycol liposomes in K562-bearing xenograft mice. Biomed Eng. 26:14500262014.
11	Hannon GJ and Rossi JJ: Unlocking the potential of the human genome with RNA interference. Nature. 431:371–378. 2004. View Article : Google Scholar : PubMed/NCBI
12	Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, et al: Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med. 359:2641–2650. 2008. View Article : Google Scholar : PubMed/NCBI
13	Petros RA and DeSimone JM: Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 9:615–627. 2010. View Article : Google Scholar : PubMed/NCBI
14	Burnett JC and Rossi JJ: RNA-based therapeutics: Current progress and future prospects. Chem Biol. 19:60–71. 2012. View Article : Google Scholar : PubMed/NCBI
15	Tabernero J, Shapiro GI, LoRusso PM, Cervantes A, Schwartz GK, Weiss GJ, Paz-Ares L, Cho DC, Infante JR, Alsina M, et al: First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 3:406–417. 2013. View Article : Google Scholar : PubMed/NCBI
16	Ozpolat B, Sood AK and Lopez-Berestein G: Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev. 66:110–116. 2014. View Article : Google Scholar : PubMed/NCBI
17	Ozpolat B, Sood AK and Lopez-Berestein G: Nanomedicine based approaches for the delivery of siRNA in cancer. J Intern Med. 267:44–53. 2010. View Article : Google Scholar : PubMed/NCBI
18	Zhou J, Shum KT, Burnett JC and Rossi JJ: Nanoparticle-based delivery of RNAi therapeutics: Progress and challenges. Pharmaceuticals (Basel). 6:85–107. 2013. View Article : Google Scholar : PubMed/NCBI
19	Allémann E, Rousseau J, Brasseur N, Kudrevich SV, Lewis K and van Lier JE: Photodynamic therapy of tumours with hexadecafluoro zinc phthalocyanine formulated in PEG-coated poly (lactic acid) nanoparticles. Int J Cancer. 66:821–824. 1996. View Article : Google Scholar : PubMed/NCBI
20	Yu B, Wang X, Zhou C, Teng L, Ren W, Yang Z, Shih CH, Wang T, Lee RJ, Tang S and Lee LJ: Insight into mechanisms of cellular uptake of lipid nanoparticles and intracellular release of small RNAs. Pharm Res. 31:2685–2695. 2014. View Article : Google Scholar : PubMed/NCBI
21	Wang Y, Xu Z, Guo S, Zhang L, Sharma A, Robertson GP and Huang L: Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis. Mol Ther. 21:1919–1929. 2013. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Paduano F, Villa R, Pennati M, Folini M, Binda M, Daidone MG and Zaffaroni N: Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells. Mol Cancer Ther. 5:179–186. 2006. View Article : Google Scholar : PubMed/NCBI
24	Kingston EF, Goulding H and Bateman AC: Vascular invasion is underrecognized in colorectal cancer using conventional hematoxylin and eosin staining. Dis Colon Rectum. 50:1867–1872. 2007. View Article : Google Scholar : PubMed/NCBI
25	Shamsabadi FT, Eidgahi MR, Mehrbod P, Daneshvar N, Allaudin ZN, Yamchi A and Shahbazi M: Survivin, a promising gene for targeted cancer treatment. Asian Pac J Cancer Prev. 17:3711–3719. 2016.PubMed/NCBI
26	Cheung CH, Huang CC, Tsai FY, Lee JY, Cheng SM, Chang YC, Huang YC, Chen SH and Chang JY: Survivin-biology and potential as a therapeutic target in oncology. Onco Targets Ther. 6:1453–1462. 2013. View Article : Google Scholar : PubMed/NCBI
27	Mobahat M, Narendran A and Riabowol K: Survivin as a preferential target for cancer therapy. Int J Mol Sci. 15:2494–2516. 2014. View Article : Google Scholar : PubMed/NCBI
28	Chen XQ, Yang S, Kang MQ, Li ZY, Lu HS and Lin TY: Survivin expression in human lung cancer and the influence of its downregulation on the biological behavior of human lung cancer cells. Exp Ther Med. 3:1010–1014. 2012.PubMed/NCBI
29	Cao C, Mu Y, Hallahan DE and Lu B: XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene. 23:7047–7052. 2004. View Article : Google Scholar : PubMed/NCBI
30	Sharma H, Sen S, Lo Muzio L, Mariggiò A and Singh N: Antisense-mediated downregulation of anti-apoptotic proteins induces apoptosis and sensitizes head and neck squamous cell carcinoma cells to chemotherapy. Cancer Biol Ther. 4:720–727. 2005. View Article : Google Scholar : PubMed/NCBI
31	Fuessel S, Kueppers B, Ning S, Kotzsch M, Kraemer K, Schmidt U, Meye A and Wirth MP: Systematic in vitro evaluation of survivin directed antisense oligodeoxynucleotides in bladder cancer cells. J Urol. 171:2471–2476. 2004. View Article : Google Scholar : PubMed/NCBI
32	Li Z, Yang S, Chang T, Cao X, Shi L and Fang G: Anti-angiogenesis and anticancer effects of a plasmid expressing both ENDO-VEGI151 and small interfering RNA against survivin. Int J Mol Med. 29:485–490. 2012.PubMed/NCBI
33	Li Z, Yin PH, Yang SS, Li QY, Chang T, Fang L, Shi LX and Fang GE: Recombinant attenuated Salmonella typhimurium carrying a plasmid co-expressing ENDO-VEGI151 and survivin siRNA inhibits the growth of breast cancer in vivo. Mol Med Rep. 7:1215–1222. 2013.PubMed/NCBI
34	Carvalho A, Carmena M, Sambade C, Earnshaw WC and Wheatley SP: Survivin is required for stable checkpoint activation in taxol-treated HeLa cells. J Cell Sci. 116:2987–2998. 2003. View Article : Google Scholar : PubMed/NCBI
35	Yang Z, Xie J, Zhu J, Kang C, Chiang C, Wang X, Wang X, Kuang T, Chen F, Chen Z, et al: Functional exosome-mimic for delivery of siRNA to cancer: In vitro and in vivo evaluation. J Control Release. 243:160–171. 2016. View Article : Google Scholar : PubMed/NCBI
36	Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, Lee CT, Lopaschuk GD, Puttagunta L, Bonnet S, et al: A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell. 11:37–51. 2007. View Article : Google Scholar : PubMed/NCBI
37	Siu RW, Fragkoudis R, Simmonds P, Donald CL, Chase-Topping ME, Barry G, Attarzadeh-Yazdi G, Rodriguez-Andres J, Nash AA, Merits A, et al: Antiviral RNA interference responses induced by Semliki Forest virus infection of mosquito cells: Characterization, origin and frequency-dependent functions of virus-derived small interfering RNAs. J Virol. 85:2907–2917. 2011. View Article : Google Scholar : PubMed/NCBI
38	Semple SC, Akinc A, Chen J, Sandhu AP, Mui BL, Cho CK, Sah DW, Stebbing D, Crosley EJ, Yaworski E, et al: Rational design of cationic lipids for siRNA delivery. Nat Biotechnol. 28:172–176. 2010. View Article : Google Scholar : PubMed/NCBI
39	Yu B, Hsu SH, Zhou C, Wang X, Terp MC, Wu Y, Teng L, Mao Y, Wang F, Xue W, et al: Lipid nanoparticles for hepatic delivery of small interfering RNA. Biomaterials. 33:5924–5934. 2012. View Article : Google Scholar : PubMed/NCBI